AUGUST 18, 2014


NRG Oncology is pleased to report the scientific articles and abstracts that have appeared or have been presented during the previous week. The publications report includes links (as available) to the article, PubMed abstract, or association abstract.

BREAST
Brufsky AM. Predictive and prognostic value of the 21-gene recurrence score in hormone receptor-positive, node-positive breast cancer. Am J Clin Oncol. 2014 Aug;37(4):404-410.  Read More

FDA approves Avastin for Aggressive and Late-Stage Cervical Cancer
The U.S. Food and Drug Administration announced approval of a new use for Avastin (bevacizumab) to treat patients with persistent, recurrent or late-stage (metastatic) cervical cancer.

Results of the GOG 0240 trial demonstrated that patients with advanced, recurrent, or persistent cervical cancer that was not curable with standard treatment who received Avastin lived longer than patients who did not receive the drug. Read the NCI press release.

NRG Oncology Introduces Weekly Broadcast

NRG Oncology introduced the Weekly Broadcast, a new e-mail communication that provides comprehensive information about NRG Oncology and its clinical trials. The Weekly Broadcast goes out to more than 8,000 people within the NRG Oncology research community and contains important information from the Operations and Statistics and Data Management Center offices that includes regulatory and protocol updates, membership information, a recent publications’ listing, and other news.

Please note, you can view the Weekly Broadcast within your email application or you can click on the “View this email in your browser” to view the Web version.

In addition, NRG Oncology will send a monthly newsletter with information about new programs, upcoming group meetings, profiles of investigators, highlights of our science to be presented at major scientific meetings and more news of interest to our research community. Be sure you are on the News Distribution List! Read more

Biologics Holiday Closure

In observance of Labor Day, Biologics, Inc. will be closed Monday, September 1. They will resume regular business hours on Tuesday, September 2. Their regular business hours are Monday through Friday 9am – 6pm ET. If you have questions, please contact the Clinical Research Services team at 800.693.4906, or via email at clinicaltrials@biologicsinc.com.

Amendments and Updates
BREAST
NSABP B-52
Amendment #1, Amendment #2, and Update #1 - NCI Version Date: February 12, 2014; Update #1 April 18, 2014.
The amended protocol and related documents can be found on the CTSU website and the B-52 page of the NSABP legacy website.RTOG 1005 (closed), Amendment 4: NCI Version Date: 7/31/2014

RTOG 1005 (closed), Amendment 4: NCI Version Date: 7/31/2014. Please see the RTOG General Broadcast page.

GYN
GOG 0286B - Amendment #2 - New language regarding the antihistamine, cimetidine has been added to the protocol and the tests and procedures that patients will undergo have been corrected in the informed consent.
The Investigator Signature Page has been updated. Please see the GOG Weekly Mailing page.

Other Protocol Notices
BREAST
NSABP B-51/RTOG 1304
A memorandum, dated August 18, 2014, regarding a Required Assessments Tool and a copy of the Assessments Tool have been posted to the B-51 pages of the NSABP legacy website and the CTSU website.

S1207/NSABP B-53
An e-mail blast, which provides highlights of the trial and can be used as a tool for investigators to keep this trial in mind, has been posted to the S1207/B-53 page of the NSABP legacy website.

Drug Safety Reports
Safety updates have been issued for GOG legacy studies. For details, please see the GOG Weekly Mailing page.

A safety update has been issued for RTOG legacy studies. For details, please see the RTOG General Broadcast page.